Reference
Shafer, S.H., et al., Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 56, 1229-1236, (1998)
Elks, M.L., and Manganiello, V.C., A role for soluble cAMP phosphodiesterases in differentiation of 3T3-L1adipocytes. J. Cell Physiol. 124, 191-198, (1985)
McKinley, J.B., et al., The interaction of adenosine analogues with cAMP-generating and cAMP-independent positive inotropic agents in rabbit left atrium. Naunyn Schmiedebergs Arch. Pharmacol. 342, 605-612, (1990)
Fearon, I.M., et al., Inhibition of recombinant human cardiac L-type Ca2+ channel α1C subunits by 3-isobutyl-1-methylxanthine. Eur. J. Pharmacol. 342, 353-358, (1998)
Freitag, A., et al., Phosphodiesterase inhibitors suppress α2-adrenoceptor-mediated 5-hydroxytryptamine release from tracheae of newborn rabbits. Eur. J. Pharmacol. 354, 67-71, (1998)
Chen, T.C., et al., Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab. Invest. 78, 165-174, (1998)
Beilstein
Beil. 26,IV,2350
reference
FT-IR 2 (3), 3670:A / FT-IR 1 (2), 711:C / IR-Spectra (3), 1288:B / IR-Spectra (2), 1120:G / NMR-Reference 2 (2), 586:D / RegBook 1 (2), 2467:K / Sigma FT-IR 1 (1), 1002:C / Structure Index 1, 390:E:4